Biotech giant Amgen is locked in a race to be one of the first to put a new type of cholesterol-lowering drug on the pharmaceutical market. The Thousand Oaks-based firm is reportedly second in line to release an alternative to statins such as Lipitor, the traditional drug used to reduce cholesterol in patients. Amgen presented…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
